Capricor Therapeutics (CAPR) Accumulated Depreciation (2012 - 2026)

Capricor Therapeutics' Accumulated Depreciation history runs 12 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• On a quarterly basis, Accumulated Depreciation rose 53.76% year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a 53.76% increase from a year earlier, with the FY2025 full-year figure at $5.2 million, up 49.29% from the prior year.
• Accumulated Depreciation advanced to $5.6 million in Q1 2026 per CAPR's latest filing, from $5.2 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $5.6 million in Q1 2026 and bottomed at $830565.0 in Q1 2022.
• The 5-year median for Accumulated Depreciation is $2.5 million (2024), against an average of $2.7 million.
• Across the five-year window, Accumulated Depreciation gained 8.2% in 2022 and surged 86.7% in 2023, its largest moves.
• Year by year, Accumulated Depreciation stood at $1.2 million in 2022, then jumped by 86.7% to $2.2 million in 2023, then soared by 56.39% to $3.5 million in 2024, then jumped by 49.29% to $5.2 million in 2025, then climbed by 9.6% to $5.6 million in 2026.
• Per Business Quant, the three latest CAPR Accumulated Depreciation figures stand at $5.6 million (Q1 2026), $5.2 million (Q4 2025), and $4.6 million (Q3 2025).